- Home
- MRK vs HBANL Comparison
MRK vs HBANL Comparison
Compare MRK & HBANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRK | HBANL |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.8B | N/A |
| IPO Year | 1997 | 2010 |
Fundamental Metrics
Financial Performance| Metric | MRK | HBANL |
|---|---|---|
| Price | $147.56 | $24.68 |
| Analyst Decision | Buy | |
| Analyst Count | 28 | 0 |
| Target Price | ★ $161.53 | N/A |
| AVG Volume (30 Days) | ★ 7.2M | 27.5K |
| Earning Date | 10-29-2026 | N/A |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | 8.01 | ★ 13.93 |
| EPS | N/A | ★ 0.92 |
| Revenue | ★ $65,011,000,000.00 | $1,562,000,000.00 |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $3.30 | N/A |
| P/E Ratio | ★ N/A | $26.91 |
| Revenue Growth | 1.31 | ★ 6.40 |
| 52 Week Low | $92.11 | $24.31 |
| 52 Week High | $157.00 | $25.98 |
Technical Indicators
Market Signals| Indicator | MRK | HBANL |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 45.03 |
| Support Level | $140.78 | $24.52 |
| Resistance Level | $154.15 | $25.29 |
| Average True Range (ATR) | 3.74 | 0.30 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 60.87 | 32.50 |
Price Performance
Historical ComparisonAbout MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About HBANL Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/40th Interest in a Share of 6.875% Series J Non-Cumulative Perpetual Preferred Stock
Huntington Bancshares is a regional US bank with over $280 billion in assets. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.